Search Results - "Denosumab therapeutic use"
-
1
Authors: et al.
Source: Revue Médicale Suisse. 21:783-787
Subject Terms: Antibodies, Monoclonal, Diphosphonates / administration & dosage, Drug Administration Schedule, Osteoporosis / complications, Osteoporosis / drug therapy, Denosumab / therapeutic use, Denosumab / administration & dosage, Diphosphonates / therapeutic use, Bone Density Conservation Agents / therapeutic use, Humans, Teriparatide / administration & dosage, Bone Density Conservation Agents / administration & dosage, Osteoporotic Fractures / prevention & control
File Description: application/pdf
-
2
Authors: et al.
Source: Archives of Osteoporosis. 20
Subject Terms: Male, Osteoporosis / diagnosis, Vitamin D / analogs & derivatives, Renal Insufficiency, Chronic / complications, Vitamin D / therapeutic use, Bone fracture, Bone turnover markers, CKD-MBD, Vascular calcification, Osteoporosis / blood, Osteoporosis / drug therapy, Denosumab / therapeutic use, Italy, Nephrology, Surveys and Questionnaires, Bone Density Conservation Agents / therapeutic use, Humans, Osteoporosis / etiology, Biomarkers / blood, Practice Patterns, Physicians' / statistics & numerical data, Female, Nephrologists / statistics & numerical data, Vitamin D / blood
File Description: application/pdf
-
3
Authors: et al.
Source: J Bone Miner Res
Subject Terms: 0301 basic medicine, Antibodies, Monoclonal / pharmacology, Bone Density / drug effects, Antibodies, Monoclonal / therapeutic use, Fractures, Bone, 03 medical and health sciences, Clinical trials, Denosumab / therapeutic use, Bone Density, Humans, Anabolics, Aged, 0303 health sciences, Fractures, Bone / epidemiology, Bone Density Conservation Agents, Antibodies, Monoclonal, Middle Aged, Bone Density Conservation Agents / pharmacology, Antiresorptives, Denosumab / pharmacology, Bone Density Conservation Agents / therapeutic use, Osteoporosis, Female, Menopause, Denosumab, Research Article
File Description: application/pdf
-
4
Authors:
Source: Cosman, F, Langdahl, B & Leder, B Z 2024, 'Treatment Sequence for Osteoporosis', Endocrine Practice, vol. 30, no. 5, pp. 490-496. https://doi.org/10.1016/j.eprac.2024.01.014
Subject Terms: 0301 basic medicine, treatment sequence, 0303 health sciences, Bone Density Conservation Agents/therapeutic use, Bone Density Conservation Agents, Diphosphonates, Osteoporosis, Postmenopausal/drug therapy, Bone Density/drug effects, osteoporosis treatment, 3. Good health, antiresorptive, Denosumab/therapeutic use, 03 medical and health sciences, Bone Density, osteoanabolic, Humans, Osteoporosis, Female, Diphosphonates/therapeutic use, Denosumab, Osteoporosis, Postmenopausal, Osteoporosis/drug therapy
Access URL: https://pubmed.ncbi.nlm.nih.gov/38311211
-
5
Authors: et al.
Source: Osteoporos Int
Lane, J, Langdahl, B, Stone, M, Kurth, A, Oates, M, Timoshanko, J, Wang, Z, Libanati, C & Cosman, F 2024, 'Romosozumab in patients who experienced an on-study fracture : post hoc analyses of the FRAME and ARCH phase 3 trials', Osteoporosis International, vol. 35, no. 7, pp. 1195-1204. https://doi.org/10.1007/s00198-024-07049-wSubject Terms: Aged, 80 and over, Bone Density Conservation Agents, Alendronate, Fracture risk, Antibodies, Monoclonal, Middle Aged, On-study fracture, Drug Administration Schedule, 3. Good health, Double-Blind Method, Bone Density, Recurrence, Romosozumab, Bone mineral density, Osteoporosis, Humans, Spinal Fractures, Original Article, Female, Denosumab, Osteoporotic Fractures, Osteoporosis, Postmenopausal, Double-Blind Method [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Antibodies, Monoclonal/therapeutic use [MeSH], Osteoporosis, Postmenopausal/complications [MeSH], Alendronate/adverse effects [MeSH], Osteoporosis, Postmenopausal/drug therapy [MeSH], Alendronate/administration, Osteoporosis, Postmenopausal/physiopathology [MeSH], Bone Density Conservation Agents/therapeutic use [MeSH], Antibodies, Monoclonal/administration, Alendronate/therapeutic use [MeSH], Female [MeSH], Bone Density Conservation Agents/administration, Bone Density/drug effects [MeSH], Humans [MeSH], Spinal Fractures/physiopathology [MeSH], Spinal Fractures/prevention, Drug Administration Schedule [MeSH], Middle Aged [MeSH], Denosumab/administration, Osteoporotic Fractures/prevention, Denosumab/therapeutic use [MeSH], Recurrence [MeSH], Bone Density Conservation Agents/adverse effects [MeSH], Denosumab/adverse effects [MeSH], Antibodies, Monoclonal/adverse effects [MeSH], Aged
-
6
Authors:
Source: Aging Clin Exp Res
Aging clinical and experimental research, vol. 37, no. 1, pp. 70Subject Terms: Humans, Denosumab/therapeutic use, Denosumab/adverse effects, Denosumab/administration & dosage, Bone Density Conservation Agents/therapeutic use, Bone Density Conservation Agents/adverse effects, Bone Density Conservation Agents/administration & dosage, Osteoporosis/drug therapy, Female, Bone Density/drug effects, Diphosphonates/therapeutic use, Denosumab, Fracture, Multiple vertebral fractures, Osteoporosis, Rebound effect, Bone Density Conservation Agents, Diphosphonates, Bone Density, Review
File Description: application/pdf
-
7
Authors: et al.
Source: Osteoporos Int
Osteoporosis international, vol. 34, no. 6, pp. 1075-1084Subject Terms: bone mineral density (BMD), Lumbar Vertebrae, Bone Density Conservation Agents, Female, Humans, Bone Density, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Cancellous Bone, Denosumab/pharmacology, Denosumab/therapeutic use, Fractures, Bone/chemically induced, Osteoporosis/drug therapy, Osteoporosis, Postmenopausal/drug therapy, Osteoporosis, Postmenopausal/chemically induced, Postmenopause, Bone mineral density (BMD), Denosumab, Osteoporosis, Postmenopausal women, Soft tissue thickness, Trabecular bone score (TBS), soft tissue thickness, postmenopausal women, denosumab, osteoporosis, 3. Good health, Fractures, Bone, Original Article, trabecular bone score (TBS), Osteoporosis, Postmenopausal
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/36862192
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_B25F15022D139
https://serval.unil.ch/notice/serval:BIB_B25F15022D13
https://serval.unil.ch/resource/serval:BIB_B25F15022D13.P001/REF.pdf
https://acuresearchbank.acu.edu.au/item/91v39/long-term-effect-of-denosumab -on-bone-microarchitecture-as-assessed-by-tissue-thickness-adjusted-trabecular-bone-score-in-postmenopausal-women-with-osteoporosis-results-from-freedom-and-its-open -
8
Authors: et al.
Source: Sølling, A S, Tsourdi, E, Harsløf, T & Langdahl, B L 2023, 'Denosumab Discontinuation', Current Osteoporosis Reports, vol. 21, no. 1, pp. 95-103. https://doi.org/10.1007/s11914-022-00771-6
Subject Terms: 0301 basic medicine, 0303 health sciences, Bone Density Conservation Agents, Fractures, Bone/chemically induced, Osteoporosis, Postmenopausal/drug therapy, 3. Good health, Denosumab/therapeutic use, Fractures, Bone, 03 medical and health sciences, Fracture, Bone Density, Bone mineral density, Humans, Osteoporosis, Female, Bone Density Conservation Agents/adverse effects, Denosumab, Bone turnover markers, Osteoporosis, Postmenopausal
Access URL: https://pubmed.ncbi.nlm.nih.gov/36564572
-
9
Authors: et al.
Source: Osteoporos Int
Osteoporosis international, vol. 33, no. 12, pp. 2517-2525Subject Terms: Freedom, 2. Zero hunger, 0301 basic medicine, 0303 health sciences, Lumbar Vertebrae, Bone Density Conservation Agents, Soft tissue thickness, Postmenopausal women, 03 medical and health sciences, 0302 clinical medicine, Absorptiometry, Photon, Bone Density, Cancellous Bone, Female, Humans, Denosumab/pharmacology, Denosumab/therapeutic use, Bone Density Conservation Agents/pharmacology, Bone Density Conservation Agents/therapeutic use, Absorptiometry, Photon/methods, Osteoporosis/drug therapy, Bone mineral density (BMD), Denosumab, Osteoporosis, Trabecular bone score (TBS), Original Article
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/36115888
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_D2734104513A3
https://serval.unil.ch/notice/serval:BIB_D2734104513A
https://serval.unil.ch/resource/serval:BIB_D2734104513A.P001/REF.pdf
https://acuresearchbank.acu.edu.au/item/8y93v/updated-trabecular-bone-score-accounting-for-the-soft-tissue-thickness-tbstt-demonstrated-significantly-improved-bone-microstructure-with-denosumab -in-the-freedom-tbs-post-hoc-analysis -
10
Authors: et al.
Contributors: et al.
Source: Osteoporosis International. 33:2409-2416
Subject Terms: Bone Density Conservation Agents, Postmenopausal* / drug therapy, Osteoporotic Fractures* / prevention & control, Postmenopausal* / complications, Antiresorptive, 3. Good health, 03 medical and health sciences, Denosumab / therapeutic use, 0302 clinical medicine, Bone Density, Teriparatide, Bone mineral density, Osteoporosis, Humans, Female, Osteoporotic Fractures* / chemically induced, Denosumab, Postmenopausal* / chemically induced, Anabolics, Osteoporosis, Postmenopausal, Osteoporotic Fractures, Retrospective Studies
Access URL: https://pubmed.ncbi.nlm.nih.gov/35925259
-
11
Authors:
Source: Acta Médica Portuguesa (2024)
Subject Terms: Denosumab/therapeutic use, Fibula, Giant Cell Tumor of Bone/drug therapy, Giant Cell Tumor of Bone/pathology, Medicine, Medicine (General), R5-920
File Description: electronic resource
-
12
Authors: et al.
Source: Osteoporos Int
Subject Terms: 0301 basic medicine, 0303 health sciences, Bone Density Conservation Agents, Diphosphonates, Muscles, Cohort Studies, 03 medical and health sciences, Bone Density, Humans, Original Article, Denosumab, Vitamin D, Propensity Score, Bone Density [MeSH], DXA, Vitamin D/pharmacology [MeSH], Humans [MeSH], Grip force, Diphosphonates [MeSH], Retrospective Studies [MeSH], Muscles [MeSH], Denosumab/therapeutic use [MeSH], Cohort Studies [MeSH], Bone Density Conservation Agents/pharmacology [MeSH], Bone Density Conservation Agents/therapeutic use [MeSH], Medical and Health Sciences, Vitamin D/therapeutic use [MeSH], Denosumab/pharmacology [MeSH], Propensity Score [MeSH], Chair rising test, Osteosarcopenia, Retrospective Studies
-
13
Authors: et al.
Source: Skeletal Radiol
Skeletal radiology, vol. 53, no. 11, pp. 2537-2543Subject Terms: Male, 0301 basic medicine, Histiocytoma, Benign Fibrous, Bone Density Conservation Agents, Case Report, Bone Neoplasms, Magnetic Resonance Imaging, Humans, Denosumab/therapeutic use, Histiocytoma, Benign Fibrous/diagnostic imaging, Histiocytoma, Benign Fibrous/surgery, Histiocytoma, Benign Fibrous/pathology, Neoplasm Recurrence, Local/diagnostic imaging, Bone Neoplasms/diagnostic imaging, Bone Neoplasms/surgery, Bone Neoplasms/drug therapy, Bone Neoplasms/pathology, Bone Density Conservation Agents/therapeutic use, Cell Transformation, Neoplastic, Female, Magnetic Resonance Imaging/methods, Tomography, X-Ray Computed, Benign fibrous histiocytoma of bone (BFHB), Cancer, Denosumab, Pelvic bone, Transformation, 03 medical and health sciences, 0302 clinical medicine, Neoplasm Recurrence, Local
File Description: application/pdf
-
14
Authors: et al.
Contributors: et al.
Source: Calcified Tissue International. 111:47-55
Subject Terms: 0301 basic medicine, Postmenopausal* / drug therapy, Raloxifene Hydrochloride / pharmacology, Bone Density Conservation Agents* / therapeutic use, 03 medical and health sciences, Denosumab / therapeutic use, 0302 clinical medicine, Bone Density, Bone mineral density, Bisphosphonate, Humans, Raloxifene Hydrochloride / therapeutic use, Osteoporosis, Postmenopausal, Aged, Bone Density Conservation Agents, Middle Aged, 3. Good health, Bone Density Conservation Agents* / pharmacology, Denosumab / pharmacology, Raloxifene Hydrochloride, Osteoporosis, Female, Denosumab, Raloxifene
Access URL: https://pubmed.ncbi.nlm.nih.gov/35226133
-
15
Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis
Authors:
Source: Osteoporos Int
Subject Terms: 03 medical and health sciences, 0302 clinical medicine, Bone Density Conservation Agents, Bone Density [MeSH], Female [MeSH], Fractures, Pregnancy, Humans [MeSH], Femur Neck [MeSH], Osteoporosis, Denosumab/therapeutic use [MeSH], Bone Density Conservation Agents/therapeutic use [MeSH], Lactation, Denosumab, Osteoporosis/drug therapy [MeSH], Pregnancy [MeSH], Case Report, Bone Density, Femur Neck, Humans, Female, 3. Good health
Access URL: https://link.springer.com/content/pdf/10.1007/s00198-021-06008-z.pdf
https://pubmed.ncbi.nlm.nih.gov/34041561
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563672
https://www.scilit.net/article/b280c91d6e54c7a4b995b56ccc5efe6b
https://pubmed.ncbi.nlm.nih.gov/34041561/
https://link.springer.com/content/pdf/10.1007/s00198-021-06008-z.pdf
https://link.springer.com/article/10.1007/s00198-021-06008-z
https://europepmc.org/article/MED/34041561
https://repository.publisso.de/resource/frl:6464895
https://epub.ub.uni-muenchen.de/90775/ -
16
Authors: et al.
Source: Revue médicale suisse, Vol. 17, No 763 (2021) pp. 2187-2191
Subject Terms: Bone Neoplasms / therapy, Giant Cell Tumor of Bone / therapy, ddc:617, 616.0757, Bone Density Conservation Agents, ddc:616.0757, 03 medical and health sciences, Denosumab / therapeutic use, Fractures, Spontaneous, Treatment Outcome, 0302 clinical medicine, Humans, Neoplasm Recurrence, Local
File Description: application/pdf
Access URL: https://archive-ouverte.unige.ch/unige:160622
-
17
Authors: et al.
Source: Revue Médicale Suisse. 17:63-67
Subject Terms: 03 medical and health sciences, Denosumab / therapeutic use, Osteoporosis / drug therapy, 0302 clinical medicine, Humans, Bone Density / drug effects, Infusions, Parenteral, Drug Approval, Zoledronic Acid / therapeutic use, Osteoporotic Fractures / prevention & control, Switzerland, Antibodies, Monoclonal / therapeutic use
File Description: application/pdf
-
18
Traitements médicamenteux séquentiels de l’ostéoporose [Sequential drug treatments for osteoporosis]
Authors: et al.
Source: Revue medicale suisse, vol. 21, no. 914, pp. 783-787
Subject Terms: Humans, Osteoporosis/drug therapy, Osteoporosis/complications, Bone Density Conservation Agents/administration & dosage, Bone Density Conservation Agents/therapeutic use, Denosumab/administration & dosage, Denosumab/therapeutic use, Diphosphonates/administration & dosage, Diphosphonates/therapeutic use, Osteoporotic Fractures/prevention & control, Teriparatide/administration & dosage, Drug Administration Schedule, Antibodies, Monoclonal
File Description: application/pdf
-
19
Authors:
Source: Sølling, A S, Harsløf, T & Langdahl, B L 2021, 'Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis : A 2-Year Randomized Study', Journal of Bone and Mineral Research, vol. 36, no. 7, pp. 1245-1254. https://doi.org/10.1002/jbmr.4305
Subject Terms: DXA, Male, 0301 basic medicine, 0303 health sciences, Bone Density Conservation Agents/therapeutic use, Bone Density Conservation Agents, Osteoporosis, Postmenopausal/drug therapy, ANTIRESORPTIVES, CLINICAL TRIAL, Middle Aged, OSTEOPOROSIS, Zoledronic Acid, Zoledronic Acid/therapeutic use, Denosumab/therapeutic use, 03 medical and health sciences, BIOCHEMICAL MARKERS OF BONE TURNOVER, Bone Density, Humans, Osteoporosis, Female, Denosumab, Osteoporosis, Postmenopausal, Osteoporosis/drug therapy
Access URL: https://pubmed.ncbi.nlm.nih.gov/33813753
https://www.ncbi.nlm.nih.gov/pubmed/33813753
https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4305
https://pubmed.ncbi.nlm.nih.gov/33813753/
https://europepmc.org/article/MED/33813753
http://pubmed.ncbi.nlm.nih.gov/33813753/
https://pure.au.dk/portal/en/publications/e22c80b1-a21a-4e48-936a-e37a526c0fba
https://doi.org/10.1002/jbmr.4305 -
20
Authors: et al.
Contributors: et al.
Source: The Lancet Oncology. 21:60-72
Subject Terms: Adult, Breast Neoplasms / drug therapy, Bone Density Conservation Agents / therapeutic use, Receptor, ErbB-2, Bone Neoplasms / drug therapy, Bone Neoplasms, Breast Neoplasms, Breast Neoplasms / metabolism, Local / metabolism, Tumor / metabolism, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Receptors, Biomarkers, Tumor, Chemotherapy, Humans, Denosumab / therapeutic use, Estrogen / metabolism, Neoplasm Staging, Bone Density Conservation Agents, Local / drug therapy, Bone Neoplasms / metabolism, Middle Aged, 16. Peace & justice, Neoadjuvant Therapy, ErbB-2 / metabolism, 3. Good health, Survival Rate, Neoplasm Recurrence, Local / pathology, Receptors, Estrogen, Chemotherapy, Adjuvant, Breast Neoplasms / pathology, Adjuvant / mortality, Female, Bone Neoplasms / secondary, Progesterone / metabolism, Denosumab, Neoplasm Recurrence, Local, Receptors, Progesterone, Biomarkers, Neoadjuvant Therapy / mortality, Receptor, Follow-Up Studies
Access URL: https://pubmed.ncbi.nlm.nih.gov/31806543
https://www.ncbi.nlm.nih.gov/pubmed/31806543
https://pubmed.ncbi.nlm.nih.gov/31806543/
https://repositorio.usp.br/item/002995190
https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(19)30687-4.pdf
https://www.sciencedirect.com/science/article/pii/S1470204519306874
http://eprints.whiterose.ac.uk/159613/
Nájsť tento článok vo Web of Science 
Full Text Finder